Sporadic Parkinson's disease: Development and distribution of α-synuclein pathology

Neuropathology and Applied Neurobiology

Volumn 42, Issue 1, 2016, Pages 33-50

  Del Tredici, K ^a   Braak, H ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Autophagy; Central nervous system; Chaperones; Dorsal motor nucleus of the vagal nerve; Enteric nervous system; Lewy pathology; Parkinson's disease; Peripheral nervous system; Protein aggregation misfolding; synuclein

Indexed keywords

ALPHA SYNUCLEIN;

AUTONOMIC DYSFUNCTION; BRAIN CORTEX; BRAIN REGION; BRAIN STEM; CENTRAL NERVOUS SYSTEM; CHOLINERGIC NERVE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; FOREBRAIN; HUMAN; IMMUNOREACTIVITY; INTESTINE INNERVATION; LEWY BODY; MOOD DISORDER; MOTONEURON NUCLEUS; NERVE PROJECTION; NONHUMAN; NORADRENERGIC NERVE; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM; POSTGANGLIONIC NERVE; PREGANGLIONIC NERVE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; PROTEIN AGGREGATION; REVIEW; SEROTONINERGIC NERVE; SLEEP DISORDER; SPINAL CORD; SUBSTANTIA NIGRA; VAGUS NERVE; ANIMAL; METABOLISM; PATHOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE PROGRESSION; ENTERIC NERVOUS SYSTEM; HUMANS; PARKINSON DISEASE;

EID: 84959186182     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12298     Document Type: Review

References (270)

1. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurology 2000; 54(Suppl 5): 21-23.
2. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003; 991: 1-14.
3. Dorsey ER, Constantinesco R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson's disease in the most populous nations, 2005 through 2030. Neurology 2005; 68: 384-6.
4. de Lau L, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5: 525-35.
5. den Hartog Jager WA, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 1960; 23: 283-90.
6. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 1988; 76: 217-21.
7. Wakabayashi K, Takahashi H. The intermediolateral nucleus and Clarke's column in Parkinson's disease. Acta Neuropathol 1997; 94: 287-9.
8. Deguchi K, Sasaki I, Tsukaguchi M, Kamoda M, Touge T, Takeuchi H, Kuriyama S. Abnormalities of rate-corrected QT intervals in Parkinson's disease - a comparison with multiple system atrophy and progressive supranuclear palsy. J Neurol Sci 2002; 199: 31-7.
9. Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K, Takahashi H. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 2007; 17: 24-30.
10. Ikemura M, Saito Y, Sengoku Y, Sakiyama Y, Hatsuta H, Kanemaru K, Sawabe M, Arai T, Ito G, Iwatsubo T, Fukayama M, Murayama S. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 2008; 67: 945-53.
11. Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson's disease. Mov Disord 2009; 24: 793-800.
12. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White CL III, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG. Arizona Parkinson's Disease Consortium. Multi-organ distribution of phophorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010; 119: 689-702.
13. Del Tredici K, Braak H. Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathol 2012; 124: 643-66.
14. Cersósimo MG, Tumilasci OR, Raina GB, Benarroch EE, Cardoso EM, Micheli F, Pazo JH. Hyposialorrhea as an early manifestation of Parkinson disease. Auton Neurosci 2009; 150: 150-1.
15. Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord 2010; 25: 2493-500.
16. Ali K, Morris HR. Parkinson's disease: chameleons and mimics. Pract Neurol 2015; 15: 14-25.
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
18. Koller WC. How accurately can Parkinson's disease be diagnosed? Neurology 1992; 42: 6-16.
19. Bloch A, Probst A, Bissig H, Adams H, Tolnay M. α-Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 2006; 12: 284-95.
20. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I. Diagnostic criteria for the neuropathological assessment of Parkinson disease. Lancet Neurol 2009; 8: 1150-7.
21. Goedert M. The awakening of α-synuclein. Nature 1997; 388: 232-3.
22. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997; 388: 839-40.
23. Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi A. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett 1997; 239: 45-8.
24. Duda JE, Lee VM, Trojanowski JQ. Neuropathology of synuclein aggregates: new insights into mechanism of neurodegenerative diseases. J Neurosci Res 2000; 61: 121-7.
25. Takahashi H, Wakabayashi K. The cellular pathology of Parkinson's disease. Neuropathology 2001; 21: 315-22.
26. Trojanowski JQ, Lee VM. Parkinson's disease and related synucleinopathies are a class of nervous system amyloidoses. Neurotoxicology 2002; 23: 457-60.
27. Trojanowski JQ, Lee VM. Meeting summary - cell biology of Parkinson's disease and related neurodegenerative disorders. Sci Aging Knowl Environ 2003; 13: 23.
28. Jellinger KA, Mizuno Y. Parkinson's disease. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 1st edn. Ed Dickson DW. Basel: ISN Neuropathol Press, 2003; 159-87.
29. Ohama E, Ikuta F. Parkinson's disease: distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol 1976; 34: 311-9.
30. Braak H, Del Tredici K. Poor and protracted myelination as a contributary factor to neurodegenerative disorders. Neurobiol Aging 2004; 25: 19-23.
31. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 2009; 201: 1-119.
32. Malek N, Swallow D, Grosset KA, Anichtchik O, Spillantini M, Grosset DG. Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review. Acta Neurol Scand 2014; 130: 59-72.
33. Lewy FH. Paralysis agitans. I. Pathologische Anatomie. In Handbuch der Neurologie. Ed Lewandowski M. Berlin: Springer, 1912; 920-33.
34. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-52.
35. Gibb WRG, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol 1989; 15: 27-44.
36. Lowe J. Lewy bodies. In DP Calne. Ed N Diseases . Philadelphia: Saunders, 1994; 51-69.
37. Braak H, Braak E, Yilmazer D, de Vos RAI, Jansen ENH, Bohl J. Jellinger K Amygdala pathology in Parkinson's disease. Acta Neuropathol 1994; 88: 493-500.
38. Braak H, Sandmann-Keil D, Gai WP, Braak E. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by α-synuclein immunocytochemistry. Neurosci Lett 1999; 265: 67-9.
39. Dickson DW, Schmidt ML, Lee VMY, Zhao ML, Yen SH, Trojanowski JQ. Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Acta Neuropathol 1994; 87: 269-76.
40. Gai WP, Blessing WW, Blumbergs PC. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease. Brain 1995; 118: 1447-59.
41. Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of α-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 2003; 62: 1241-53.
42. Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S. Accumulation of phosphorylated α-synuclein in aging human brain. J Neuropathol Exp Neurol 2003; 62: 644-54.
43. Fearnley JM, Lees AJ. Pathology of Parkinson's disease. In Neurodegenerative Diseases. Ed DB Calne . Philadelphia: Saunders, 1994; 545-54.
44. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55: 259-72.
45. Dickson DW. α-Synuclein and the Lewy body disorders. Curr Opin Neurol 2001; 14: 423-32.
46. Goedert M. The significance of tau and α-synuclein inclusions in neurodegenerative diseases. Curr Opin Genet Dev 2001; 11: 343-51.
47. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol 2013; 9: 13-24.
48. Norris EH, Giasson BI, Lee VM. α-Synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol 2004; 60: 17-54.
49. Tofaris GK, Spillantini MG. Physiological and pathological properties of alpha- synuclein. Cell Mol Life Sci 2007; 64: 2194-201.
50. Stamelou M, Hoeglinger GU. Atypical parkinsonism: an update. Curr Opin Neurol 2013; 26: 401-5.
51. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, Curran MD, Court JA, Mann DM, Ikeda S, Cookson MR, Hardy J, Allsop D. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003; 17: 1945-7.
52. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P, Chilcote TJ. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 2008; 5: 55-9.
53. Braak H, Del Tredici K, Gai WP, Braak E. Alpha-synuclein is not a requisite component of synaptic boutons in the adult human central nervous system. J Chem Neuroanat 2001; 20: 245-52.
54. Clayton DF, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 1999; 58: 120-9.
55. Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, Edwards RH. Neural activity controls the synaptic accumulation of α-Synuclein. Neurobiol Dis 2005; 25: 10913-21.
56. Stefanis L. α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med 2012; 4: a009399.
57. Anichtchik O, Calo L, Spillantini MG. Synaptic dysfunction in synucleinopathies. CNS Neurol Disord Drug Targets 2013; 12: 1094-100.
58. Lashuel HA, Overk CA, Queslati A, Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 2013; 14: 38-48.
59. Silva BA, Breydo L, Uversky VN. Targeting the chameleon: a focused look at α-synuclein and its roles in neurodegeneration. Mol Neurobiol 2013; 47: 446-59.
60. Goedert M. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein. Science 2015; 349: 125555.
61. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001; 276: 2380-6.
62. Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, Shi D, Sangwan S, Guenther EL, Johnson LM, Zhang M, Jiang L, Arbing MA, Nannenga BI, Hattne J, Whitelegge J, Brewster AS, Messerschmidt M, Boutet S, Sauter NK, Gonen T, Eisenberg DS. Structure of the toxic core of α-synuclein from invisible crystals. Nature 2015; 525: 486-90.
63. Goedert M, Cheng Y. Parkinson's disease: crystals of a toxic core. Nature 2015; 525: 458-9.
64. Bartels T, Choi JG, Selkoe DJ. α-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011; 477: 107-10.
65. Witt SN. Molecular chaperones, α-synuclein, and neurodegeneration. Mol Neurobiol 2013; 47: 552-60.
66. Selkoe D, Dettmer U, Luth E, Kim N, Newman A, Bartels T. Defining the native state of α-synuclein. Neurodegener Dis 2014; 13: 114-7.
67. Dettmer U, Newman AJ, Soldner F, Luth ES, Kim NC, vonSaucken VE, Sanderson JB, Jaenisch R, Bartels T, Selkoe D. Parkinson-causing a-synuclein missense mutations shift native tetramers to monomers as a mechanism of disease. Nat Commun 2015; 6: 7314.
68. Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT, Tsika E, Coune P, Prudent M, Lion N, Eliezer D, Moore DJ, Schneider B, Aebischer P, El-Agnaf OM, Masliah E, Lashuel HA. a-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 2012; 287: 15345-64.
69. Burré J, Vivona S, Sidao J, Sharma M, Brunger AT, Sudhof TC. Properties of native brain α-Synuclein. Nature 2013; 498: E4-7.
70. Kim WS, Kägedal K, Halliday GM. Alpha-synuclein biology in Lewy body disease. Alzheimers Res Ther 2014; 6: 73.
71. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-210.
72. Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T, Tsuchiya K, Mori F, Wakabayashi K, Takahashi H. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005; 109: 583-8.
73. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72: 57-71.
74. Recasens K, Dehay B, Bove J, Carballo-Carbaja L, Dovero S, Pérez-Villaba A, Fernagut PO, Biesa J, Parent A, Perier C, Fariñas I, Obeso JA, Bezard E, Vila M. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014; 75: 351-62.
75. Tanji K, Mori F, Mimura J, Itho K, Kakita A, Takahashi H, Wakabyashi K. Proteinase K-resistant α-synuclein is deposited in presynapses in human Lewy body disease and A53T α-synuclein transgenic mice. Acta Neuropathol 2010; 120: 145-54.
76. Pieri L, Madiona K, Bousset L, Melki R. Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to cells. Biophys J 2012; 102: 2894-905.
77. Prasad K, Beach TG, Hedreen J, Richfield EK. Critical role for truncated α-synuclein and aggregates in Parkinson's disease and incidental Lewy body disease. Brain Pathol 2012; 22: 811-25.
78. Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA, Meissner WG. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol 2015; 14: 855-66.
79. Leigh PN, Probst A, Dale GE, Power DP, Brion JP, Dodson A, Anderton BH. New aspects of the pathology of neurodegenerative disorders as revealed by ubiquitin antibodies. Acta Neuropathol 1989; 79: 61-72.
80. Lennox G, Lowe J, Landon M, Byrne EJ, Mayer RJ, Godwin-Austen RB. Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry 1989; 52: 1236-47.
81. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 1990; 79: 581-3.
82. Wakabayashi K, Tanji K, Mori F, Takahashi H. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007; 27: 494-506.
83. Wakabayashi K, Tanji K, Odagiri S, Odagiri S, Miki Y, Mori F, Takahashi H. The Lewy body in Parkinson's disease and related neurodegenerative disorders. Mol Neurobiol 2013; 47: 495-508.
84. Katsuse O, Iseki E, Marui W, Kosaka K. Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J Neurol Sci 2003; 211: 29-35.
85. Dugger BN, Dickson DW. Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta Neuropathol 2010; 120: 633-9.
86. Miki Y, Tanji K, Mori F, Utsumi J, Sasaki H, Kakita A, Takahashi H, Wakabyashi K. Alteration of upstream autophagy-related proteins (ULK1, ULK2, Beclin1, VPS34, and AMBRA1) in Lewy body disease. Brain Pathol 2015; doi: 10.1111/bpa.12297.
87. Volles M, Lansbury PJ. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003; 42: 7871-8.
88. Chung KK, Dawson VL, Dawson TM. The role of the ubiquitin-proteosomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci 2001; 24: 7-14.
89. McNaught KS, Jenner P. Proteosomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 2001; 297: 191-4.
90. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science 2004; 305: 1292-5.
91. Martinez-Vincente M, Cuervo AM. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol 2007; 6: 352-61.
92. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 2009; 35: 385-98.
93. Dehay B, Bové J, Rodriguez-Muela N, Recasens A, Boya P, Vila M. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 2010; 30: 12535-44.
94. Lynch-Day M, Mao K, Wang K, Zhao M, Klionsky DJ. The role of autophagy in Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2: a009357.
95. Duda JE. Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004; 17: 3-14.
96. Saha AR, Hill J, Utton MA, Assuni AA, Ackerley S, Grierson AJ, Miller CC, Davies AM, Buchman VL, Anderton BH, Hanger DP. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J Cell Sci 2004; 117: 1017-24.
97. Kanazawa T, Adachi E, Orimo S, Nakamura A, Mizusawa H, Uchichara T. Pale neurites, premature α-synuclein aggregates with centripetal extension from axon collaterals. Brain Pathol 2012; 22: 67-78.
98. Roy S, Zhang B, Lee VM, Trojanowski JQ. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol 2005; 109: 5-13.
99. Lamberts JT, Hildebrandt EN, Brundin P. Spreading of α-synuclein in the face of axonal transport deficits in Parkinson's disease: a speculative synthesis. Neurobiol Dis 2015; 77: 276-83.
100. Herrup K, Yang Y. Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nat Rev Neurosci 2007; 8: 368-78.
101. Webb J, Ravikumar B, Athkins J, Skepper J, Rubinsztein D. Alpha-Synuclein is degraded by both autophagy and the proteosome. J Biol Chem 2003; 278: 25009-13.
102. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42.
103. Breydo L, Wu JW, Uversky VN. A-synuclein misfolding and Parkinson's disease. Biochim Biophys Acta 2012; 1822: 261-85.
104. Bandopadhyay R, de Belleroche J. Pathogenesis of Parkinson's disease: emerging role of molecular chaperones. Trends Mol Med 2010; 16: 27-36.
105. Cox D, Carber JA, Ecroyd H. Preventing α-synuclein aggregation: the role of the small heat-shock molecular chaperone proteins. Biochim Biophys Acta 2014; 1842: 1830-43.
106. Zhou L, Miranda-Saksena M, Saksena NK. Viruses and neurodegeneration. J Virol 2013; 10: 172-86.
107. Marreiros R, Müller-Schiffmann A, Bader V, Selvarajah S, Dey D, Lingappa VR, Korth C. Viral capsid assembly as a model for protein aggregation diseases: active processes catalyzed by cellular assembly machines composing novel drug target. Virus Res 2015; 207: 155-64.
108. Orimo S, Kanazawa T, Itoh Y, Wakabayashi K, Kakita A. Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson's disease. Neuropathol Appl Neurobiol 2011; 37: 791-802.
109. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004; 3: 309-16.
110. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59: 591-6.
111. Ahlskog JE. Beating a dead horse: Dopamine and Parkinson's disease. Neurology 2007; 69: 1701-11.
112. Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, Burnett M, Parisi JE, Klos KJ, Ahlskog JE. Neuropathology of non-motor features of Parkinson's disease. Parkinsonism Rel Disord 2009; 15(Suppl 3): S1-S5.
113. Halliday GM, Lees AJ, Stern M. Milestones in Parkinson's disease - clinical and pathologic features. Mov Disord 2011; 26: 1015-21.
114. Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Adv Neurol 1993; 60: 609-12.
115. Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, Satoh A, Seto M, Tsujihata M, Takahashi H. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 1999; 52: 1269-71.
116. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006; 396: 67-72.
117. Klos KJ, Ahlskog JE, Josephs KA, Apaydin H, Parisi JE, Boeve BF, DeLucia MW, Dickson DW. α-Synuclein pathology in the spinal cord of neurologically asymptomatic aged individuals. Neurology 2006; 66: 1100-2.
118. Ross GW, Abbott RD, Petrovitch H, Tanner CM, Davis DG, Nelson J, Markesbery WR, Hardman J, Masaki K, Launer L, White LR. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 2006; 21: 2062-7.
119. Abbott RD, Ross GW, Petrovitch H, Tanner CM, Davis DG, Masaki KH, Launer LJ, Curb JD, White LR. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007; 22: 1581-6.
120. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, Ortega-Moreno A, Rebollo AC, Gomez-Rio M, Concha A, Munoz DG. Do α-synuclein aggregates in autonomic plexuses predate Lewy body disorders? A cohort study Neurology 2007; 68: 2012-8.
121. DelleDonne A, Klos KJ, Fujishiro H, Ahmed Z, Parisi JR, Josephs KA, Frigerio R, Burnett M, Wszolek ZK, Uitti RJ, Ahlskog JE, Dickson DW. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 2008; 65: 1074-80.
122. Dickson DW, Fujishiro H, DelleDonne A, Menke J, Zeshan A, Klos K, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE. Evidence that incidental Lewy body disease is presymptomatic Parkinson's disease. Acta Neuropathol 2008; 115: 437-44.
123. Markesbery WR, Jicha GA, Liu H, Schmitt FA. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 2009; 68: 816-22.
124. Savica R, Rocca WA, Ahlskog R. When does Parkinson disease start? Arch Neurol 2010; 67: 798-801.
125. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 2010; 119: 703-13.
126. Del Tredici K, Braak H. Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov Disord 2012; 27: 597-607.
127. Shannon KM, Deshavarzian A, Mutlu E, Dodiya D, Jaglin JA, Kordower JH. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2012; 27: 709-15.
128. Tamura T, Yoshida M, Hashizume Y, Sobue G. Lewy body-related α-synucleinopathy in the spinal cord of cases with incidental Lewy body disease. Neuropathology 2012; 32: 13-22.
129. Navarro-Otano J, Gelpi E, Mestres CA, Quintana E, Rauek S, Ribalta T, Santiago V, Tolosa E. Alpha-synuclein aggregates in epicardial fat tissue in living subjects without parkinsonism. Parkinsonism Rel Disord 2013; 19: 27-31.
130. Milber JM, Noorigian JV, Morley JF, Petrovitch H, White L, Ross GW, Duda JE. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson's disease. Neurology 2012; 79: 2307-14.
131. Tolosa E, Gaig C, Santamaria J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology 2009; 72(7 Suppl): S12-S20.
132. Schapira AH, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 2010; 6: 309-17.
133. Olanow CW, Obeso JA. The significance of defining preclinical or prodromal Parkinson's disease. Mov Disord 2012; 27: 666-9.
134. Boeve BF. Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol 2013; 12: 469-82.
135. Chen H, Burton EA, Ross GW, Huang X, Savica R, Abbott RD, Ascherio A, Caviness JN, Gao X, Gray KA, Hong JS, Kamel F, Jennings D, Kirshner A, Lawler C, Liu R, Miller GW, Nussbaum R, Peddada SD, Rick AC, Ritz B, Siderowf AD, Tanner CM, Tröster AI, Zhang J. Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications. Envior Health Perspect 2013; 121: 1245-52.
136. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 138-42.
137. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 436-46.
138. Hawkes CH, Shephard BC, Daniel SE. Is Parkinson's disease a primary olfactory disorder? Q J Med 1999; 92: 473-80.
139. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Rel Disord 2010; 16: 79-84.
140. Doty RL. Olfaction. Ann Rev Psychol 2001; 52: 423-52.
141. Doty RL. Olfactory dysfunction in Parkinson disease. Nat Rev Neurol 2012; 8: 329-39.
142. Hawkes CH. Olfaction in neurodegenerative disorder. Mov Disord 2003; 18: 364-72.
143. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56: 173-81.
144. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 2007; 30: 839-42.
145. Korczyn AD. Autonomic nervous system disturbances in Parkinson's disease. Adv Neurol 1990; 53: 463-8.
146. Edwards LI, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991; 6: 151-6.
147. Abbot RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001; 57: 456-62.
148. Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-45.
149. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008; 15(Suppl 1): 14-20.
150. Lang AE. A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord 2011; 26: 775-83.
151. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Rel Disord 2011; 17: 10-5.
152. Cersósimo MG, Benarroch EE. Autonomic involvement in Parkinson's disease: pathology pathophysiology, clinical features and possible peripheral biomarkers. J Neurol Sci 2012; 313: 57-63.
153. Cersósimo MG, Perandonas C, Micheli FE, Raina GB, Beron AM, Nassetter G, Radrizanni M, Benarroch EE. Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients. Mov Disord 2011; 26: 188-90.
154. Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, Ziemssen T. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012; 27: 617-26.
155. Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O'Brien JT, Brooks RA, Burn DJ. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013; 80: 276-81.
156. Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, Broughton E, Hagan H, Carroll C. Accumulation of α-synuclein in the bowel of patients in the pre-clinical pahse of Parkinson's disease. Acta Neuropathol 2014; 127: 235-41.
157. Stiasny-Kolster K, Doerr Y, Möller JC, Höffken H, Behr TM, Oertel WH, Mayer G. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005; 128: 126-37.
158. Boeve BF, Saper CB. REM sleep behavior disorder: a possible early marker for synucleinopathies. Neurology 2006; 28: 796-7.
159. Korczyn A, Gurevich T. Parkinson's disease: before the motor symptoms and beyond. J Neurol Sci 2010; 289: 2-6.
160. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54: 1916-21.
161. Apaydin H, Ahlskog J, Parisi J, Boeve B, Dickson D. Parkinson's disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59: 102-12.
162. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-44.
163. Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, Caviness JN, Shill HA, Sue LI, Ziabreva I, Perry E, Ballard CG, Aarsland D, Walker DG, Beach TG. Parkinson's disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009; 23: 295-7.
164. Reid WG, Hely MA, Morris JG, Loy C, Halliday GM. Dementia in Parkinson's disease: a 20-year neuropsychologicl study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry 2011; 82: 1033-7.
165. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM, Leverenz JB, Montine TJ, Duda JE, Hurtig HI, Trojanowski JQ. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012; 72: 587-98.
166. Pinter B, Diem-Zangert A, Wenning GK, Scherfler C, Oberaigner W, Seppi K, Poewe W. Mortality in Parkinson's disease: a 38-year follow-up study. Mov Disord 2015; 30: 266-9.
167. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007; 33: 599-614.
168. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: the dual hit theory revisited. Ann N Y Acad Sci 2009; 1170: 615-22.
169. Gaig C, Tolosa E. When does Parkinson's disease begin? Mov Disord 2009; 24(Suppl 2): S656-S664.
170. Halliday GM, Holton JL, Revesz R, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011; 122: 187-204.
171. van de Berg WD, Hepp DH, Dijkstra AA, Rozemuller JA, Berendse HW, Foncke E. Patterns of alpha-synuclein pathology in incidental cases and clinical subtypes of Parkinson's disease. Parkinsonsim Relat Disord 2012; 18(Suppl 1): S28-S30.
172. Jenner P, Morris HR, Robbins TW, Goedert M, Hardy H, Ben-Schlomo Y, Bolam P, Burn D. Parkinson's disease: the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J Parkinsons Dis 2013; 3: 1-11.
173. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tiss Res 2004; 318: 121-34.
174. Braak H, Müller CM, Bohl JR, Rüb U, de Vos RAI, Del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson disease reconsidered. Mov Disord 2006; 21: 2042-51.
175. Sengoku R, Saito Y, Ikemura M, Hatsuta H, Sakiyama Y, Kanemaru K, Arai T, Sawabe M, Tanaka N, Mochizuki H, Inoue K, Shigeo S. Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J Neuropathol Exp Neurol 2008; 67: 1072-83.
176. Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y. Evidence in favor of Braak staging of Parkinson's disease. Mov Disord 2010; 25(Suppl 1): S78-S82.
177. Halliday GM, McCann H, Shepherd C. Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease? Exp Rev Neurother 2012; 12: 673-86.
178. Uchihara T, Giasson BI. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human studies. Acta Neuropathol 2016; 131: 49-73.
179. Del Tredici K, Rüb U, de Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002; 61: 413-26.
180. Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson's disease. Mov Disord 1995; 10: 283-7.
181. Duda JE, Shah U, Arnold SE, Lee VM, Trojanowski JQ. The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa. Exp Neurol 1999; 60: 515-22.
182. Watelet JR, Strolin-Benedetti M, Whomsley R. Defense mechanisms of olfactory neuro-epithelium: mucosa regeneration, metabolising enzymes and transporters. B-ENT 2009; 5(Suppl 13): 21-37.
183. Beach TG, Adler CH, Lue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL III, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009; 117: 613-34.
184. Baker H, Genter MB. The olfactory system and the nasal mucosa as portals of entry of viruses, drugs, and other exogenous agents into the brain. In Handbook of Olfaction and Gustation. Ed Doty RL. New York: Marcel Dekker, 2003; 549-73.
185. Hubbard PS, Esiri MM, Reading M, McShane R, Nagy Z. Alpha-synuclein pathology in the olfactory pathways of dementia patients. J Anat 2007; 211: 117-24.
186. Doty RL. The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol 2008; 63: 7-15.
187. Lerner A, Bagic A. Olfactory pathogenesis of idiopathic Parkinson's disease revisited. Mov Disord 2008; 23: 1076-84.
188. Rey NL, Petit GH, Bousset L, Melki R, Brundin P. Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 2013; 126: 555-73.
189. Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, Keshavarzian A. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS ONE 2011; 6: e28032.
190. Kuo YM, Li Z, Jiao Y, Gaborit N, Pani AK, Orison BM, Bruneau BG, Giasson BI, Smeyne RJ, Gershon MD, Nussbaum RL. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 2010; 19: 1633-50.
191. De Chiara G, Marcocci ME, Sgarbanti R, Civitelli L, Ripoli C, Piacentini R, Garaci E, Grassi C, Palamara AT. Infectious agents in neurodegeneration. Mol Neurobiol 2012; 46: 614-38.
192. Benarroch EE. The locus ceruleus norepinephrine system. Functional organization and potential clinical significance. Neurology 2009; 17: 1699-704.
193. Nieuwenhuys R. The greater limbic system, the emotional motor system and the brain. Prog Brain Res 1996; 107: 551-80.
194. Nieuwenhuys R, Voogd J, van Huijzen C. The Human Central Nervous System, 4th edn. Berlin, Heidelberg: Springer, 2008.
195. Braak H, Rüb U, Sandmann-Keil D, Gai WP, de Vos RA, Jansen Steur EN, Arai K, Braak E. Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol 2000; 99: 489-95.
196. Sumikura H, Takao M, Hatsuta H, Ito S, Uchino A, Nogami A, Saito Y, Mochizuki H, Murayama S. Distribution of α-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons. Acta Neuropathol Comm 2015; 3: 57.
197. VanderHorst V, Samardzic T, Saper CB, Anderson MP, Nag S, Schneider JA, Bennett DA, Buchman AS. α-Synuclein pathology accumulates in sacral spinal visceral sensory pathways. Ann Neurol 2015; 78: 142-9.
198. Braak H, Sastre M, Bohl JRE, de Vos RA, Del Tredici K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007; 113: 421-9.
199. Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, Funk RHW. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS ONE 2010; 5: e8762.
200. Sims KS, Williams RS. The human amygdaloid complex: a cytologic and histochemical atlas using Nissl, myelin, acetylcholinesterase and nicotinamide adenine dinucleotide phosphate diaphorase staining. Neuroscience 1990; 36: 449-72.
201. Liubashina O, Jolkkonen E, Pitkänen A. Projections from the central nucleus of the amygdala to the gastric related area of the dorsal vagal complex: a Phaseolus vulgaris leucoagglutinin study in rat. Neurosci Lett 2000; 291: 85-8.
202. Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson's disease. Brain 2000; 123: 1767-83.
203. Collingridge GL, James TA, MacLeod NK. Neurochemical and electrophysiological evidence for a projection from the locus coeruleus to the substantia nigra. J Physiol 1979; 290: 44.
204. Fudge JL, Haber SN. The central nucleus of the amygdala projection to dopamine subpopulations in primates. Neuroscience 2000; 97: 479-94.
205. Strack AM, Sawyer WB, Hughes JH, Platt KB, Loewy AD. A general pattern of CNS innervation of the sympathetic outflow demonstrated by transneuronal pseudorabies viral infections. Brain Res 1989; 491: 156-62.
206. Morrison LA, Sidman RL, Fields BN. Direct spread of reovirus from the intestinal lumen to the central nervous system through vagal autonomic nerve fibers. Proc Natl Acad Sci USA 1991; 88: 3852-6.
207. Kristensson K. Potential role of viruses in neurodegeneration. Mol Chem Neuropathol 1992; 16: 45-58.
208. Card JP. Exploring brain circuitry with neurotropic viruses: new horizons in neuroanatomy. Anat Rec 1998; 253: 176-85.
209. Rinaman L, Levitt P, Card JP. Progressive postnatal assembly of limbic-autonomic circuits revealed by central transneuronal transport of pseudorabies virus. J Neurosci 2000; 20: 2731-41.
210. Jang H, Boltz D, Sturm-Ramirez K, Shepherd KR, Jiao Y, Webster R, Smeyne RJ. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeration. Proc Natl Acad Sci USA 2009; 106: 14063-8.
211. McCann H, Cartwright H, Halliday GM. Neuropathology of α-synuclein propagation and Braak hypothesis. Mov Disord 2015; doi: 10.1002/mds.26421.
212. Braak H, Braak E. The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci Res 1992; 15: 6-31.
213. Braak H, Del Tredici K. The preclinical phase of the pathological process underlaying sporadic Alzheimer's disease. Brain 2015; 138: 2814-33.
214. Gloor P. The Temporal Lobe and Limbic System. New York: Oxford University Press, 1997.
215. Amunts K, Kedo O, Kindler M, Pieperhoff P, Mohlberg H, Shah NJ, Habel U, Schneider F, Zilles K. Cytoarchitectonic mapping of the human amygdala, hippocampal region and entorhinal cortex: intersubject variability and probability maps. Anat Embryol 2005; 210: 343-52.
216. Amunts K, Zilles K. Advances in cytoarchitectonic mapping of the human cerebral cortex. Neuroimaging Clin N Am 2001; 11: 151-69.
217. Wakabayashi K, Hansen LA, Masliah E. Cortical Lewy body-containing neurons are pyramidal cells: laser confocal imaging of double-immunolabeled sections with anti-ubiquitin and SMI32. Acta Neuropathol 1995; 89: 404-8.
218. Barbas H, Rempel-Clower N. Cortical structure predicts the pattern of corticocortical connections. Cereb Cortex 1997; 7: 635-46.
219. Bannister AP. Inter- and intra-laminar connections of pyramidal cells in the neocortex. Neurosci Res 2005; 53: 95-103.
220. Barbas H. Specialized elements of orbitofrontal cortex in primates. Ann N Y Acad Sci 2007; 1121: 10-32.
221. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003; 110: 517-36.
222. Reichmann H. View point: etiology in Parkinson's disease. Dual hit or spreading intoxication. J Neurol Sci 2011; 310: 9-11.
223. Pan-Montojo F, Reichmann H. Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiology. Transl Neurodegener 2014; 3: 10.
224. Nakamura K, Mori F, Tanji K, Miki Y, Toyoshima Y, Kakita A, Takahashi H, Yamada M, Wakabayashi K. α-Synuclein pathology in cranial and spinal nerves in Lewy body disease. Neuropathology 2015; doi: 10.111/neup.12269.
225. Richards WG, Sugarbaker DJ. Neuronal control of esophageal function. Chest Surg Clin N Am 1995; 5: 157-71.
226. Benarroch EE. Enteric nervous system: functional organization and neurologic implications. Neurology 2007; 69: 1953-7.
227. Cersósimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 2008; 23: 1065-75.
228. Fuminura Y, Ikemura M, Saito Y, Sengoku R, Kanemaru K, Sawabe M, Arai T, Ito G, Iwatsubo T, Fukayama M, Mizusawa H, Murayama S. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in Lewy body disease. J Neuropathol Exp Neurol 2007; 66: 354-62.
229. Miki Y, Mori F, Wakabayashi K, Kuroda N, Orimo S. Incidental Lewy body disease restricted to the heart and stellate ganglia. Mov Disord 2009; 24: 2299-301.
230. Desplats P, Lee H-J, Bae E-J, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee S-J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc Natl Acad Sci USA 2009; 106: 13010-5.
231. Hansen C, Angot E, Bergström AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li JY, Brundin P. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121: 715-25.
232. Miwa H, Kubo T, Suzuki A, Kondo T. Intragastric proteasome inhibition induces alpha-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats. Neurosci Lett 2006; 401: 146-9.
233. Ulusoy A, Rusconi R, Perez-Revuelta BI, Musgrove RE, Helwig M, Winzen-Reichert B, Di Monte DA. Caudo-rostral brain spreading of alpha synuclein through vagal connections. EMBO Mol Med 2013; 5: 1051-9.
234. Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björkland T, Wang ZY, Roybon L, Melki R, Li J-Y. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 2014; 128: 805-20.
235. Sacino AN, Brooks J, Thomas MA, McKinney AB, Lee S, Regenhardt RW, McGarvey NH, Ayers JI, Notterpek L, Borchelt DR, Golde TE, Giasson BI. Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci USA 2014; 111: 10732-7.
236. Phillips RJ, Walter GC, Wilder SL, Baronowski EA, Powley TL. Alpha-synuclein immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? Neuroscience 2008; 153: 733-50.
237. Norrian AR, Rha J, Annerino DM, Bernhard D, Taylor GM, Greene JG. Alpha-synuclein transgenic mice display age-related slowing of gastrointenstinal motility associated with transgene expression in the vagal system. Neurobiol Dis 2012; 48: 9-19.
238. Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, Sørensen HT. Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol 2015; 78: 522-9.
239. Hopkins DA, Bieger D, de Vente J, Steinbusch HWM. Vagal efferent projections: viscerotopy, neurochemistry and effects of vagotomy. Progr Brain Res 1996; 107: 79-96.
240. Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O'Sullivan GA, Pal A, Said J, Marsico G, Verbavatz JM, Rodrigo-Angulo M, Gille G, Funk RH, Reichmann H. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2012; 2: 898.
241. Saper CB, Wainer BH, German DC. Axonal and transneuronal transport in the transmission of neurological disease: potential role in system degenerations, including Alzheimer's disease. Neuroscience 1987; 23: 389-98.
242. Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci 2008; 9: 741-5.
243. Angot E, Steiner JA, Hansen C, Li JY, Brundin P. Are synucleinopathies prion-like disorders? Lancet Neurol 2010; 9: 1128-38.
244. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 2010; 33: 317-25.
245. Goedert M, Falcon B, Clavaguera F, Tolnay M. Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr Neurol Neurosci Rep 2014; 14: 495.
246. Steiner JA, Angot E, Brundin P. A deadly spread: cellular mechanisms of α-synuclein transfer. Cell Death Differ 2011; 18: 1425-33.
247. Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg CR, McLean PJ. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodebener 2012; 7: 42.
248. Dunning CJ, Reyes JF, Steiner JA, Brundin P. Can Parkinson's disease pathology be propagated from neuron to another? Prog Neurobiol 2012; 97: 205-19.
249. Hansen C, Li JY. Beyond alpha-synuclein transfer: pathology propagation in Parkinson's disease. Trends Mol Med 2012; 18: 248-55.
250. Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B, Madiona K, Olieric V, Böckmann A, Meier BH, Melki R. Structural and functional characterization of two alpha-synuclein strains. Nat Commun 2013; 4: 2575.
251. George S, Rey NL, Reichenbach N, Steiner JA, Brundin P. α-Synuclein; the long distance runner. Brain Pathol 2013; 23: 350-7.
252. Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013; 501: 45-51.
253. Olanow CW, Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord 2013; 28: 31-40.
254. Sacino AN, Giasson BI. Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology? Alzheimers Res Ther 2013; 4: 48.
255. Luk KC, Lee VM. Modeling Lewy body propagation in Parkinson's disease. Parkinsonism Related Disord 2014; 20 Suppl 1: S85-S87.
256. Recasens A, Dehay B. Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat 2014; 8: 1-9.
257. Tran HT, Chung CH, Iba M, Zhang B, Trojanowski JQ, Luk KC, Lee VM. A-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Rep 2014; 7: 2054-65.
258. Herva ME, Spillantini MG. Parkinson's disease as a member of prion-like disorders. Virus Res 2015; 207: 38-46.
259. Melki R. Role of different alpha-synuclein strains in synucleinopathies, similarities with other neurodegenerative diseases. J Parkinson's Dis 2015; 5: 217-27.
260. Peelaerts W, Bousset L, Van der Peren A, Moskalyuk A, Pulizzi R, Giugliano M, Van den Haute C, Melki R, Baekelandt V. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015; 522: 340-4.
261. Kamel F, Goldman SM, Umbach DM, Chen H, Richardson G, Barber RM, Meng C, Marras C, Korell M, Kasten M, Hoppin JA, Comyns K, Chade A, Blair A, Bhudhikanok GS, Webster Ross G, Langston JW, Sandler DP, Tanner CM. Dietary fat intake, pesticide use, and Parkinson's disease. Parkinsonism Relat Disord 2015; 20: 82-7.
262. Büttner T, Patzold T, Kuhn W, Müller T, Przuntek H. Impaired color discrimination in Parkinson's disease. Neuoophtahl 1994; 14: 91-5.
263. Haug BA, Kolle RU, Trenkwalder C, Oertel WH, Paulus W. Predominant affection of the blue cone pathway in Parkinson's disease. Brain 1995; 118: 771-8.
264. Nolano M, Provitera V, Estraneo A, Selim MM, Caaporaso G, Stancanelli A, Saltalamacchia AM, Lanzillo B, Santoro L. Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain 2008; 131: 1903-11.
265. Doppler K, Ebert S, Uçeyler N, Trenkwalder C, Ebentheuer J, Volkmann J, Sommer C. Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. Acta Neuropathol 2014; 128: 99-109.
266. Kaur M, Saxena R, Singh D, Behari M, Sharma P, Menon V. Correlation between structural and functional retinal changes in Parkinson disease. J Neuroophthalmol 2015; 35: 254-8.
267. Mu L, Chen J, Sobotka S, Nyirenda T, Benson B, Gupta F, Sanders I, Adler CH, Caviness JN, Shill HA, Sabbagh M, Samanta JE, Sue LI, Beach TG; Arizona Parkinson's Disease Consortium. Alpha-synuclein pathology in sensory nerve terminals of the upper aerodigestive tract of Parkinson's disease patients. Dysphagia 2015; 30: 404-17.
268. Costa M, Brookes SJ, Hennig GW. Anatomy and physiology of the enteric nervous system. Gut 2000; 47(Suppl 4): 15-19.
269. Furness JB. Types of neurons in the enteric nervous system. J Auton Nerv Syst 2000; 81: 87-96.
270. Aldecoa I, Navarro-Otano J, Stefanova N, Sprenger FS, Seppi K, Poewe W, Cuatrecasas M, Valldeoriola F, Gelpi E, Tolosa E. Alpha-synuclein immunoreactivity paterns in the enteric nervous system. Neurosci Lett 2015; 602: 145-9.